Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Moxifloxacin hydrochloride
Drug ID BADD_D01502
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status approved; investigational
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D00874
MeSH ID D000077266
PubChem ID 101526
TTD Drug ID D0ZV0Z
NDC Product Code 48943-0025; 55111-064; 58032-0131; 40032-034; 60429-893; 50370-0001; 51927-4833; 51991-943; 72789-037; 29967-0005; 49574-522; 63323-850; 65862-627; 0093-7387; 50090-4100; 70518-3738; 51927-0167; 0781-7135; 49587-106; 50090-4058; 66298-8507; 67296-1616; 67457-323; 72789-038; 13668-201; 0078-0939; 65862-603; 68084-722; 0832-1410; 50268-576; 51927-0089; 57237-156
UNII C53598599T
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H25ClFN3O4
CAS Registry Number 186826-86-8
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Salpingitis21.14.03.001; 11.01.10.001--Not Available
Seizure17.12.03.001--
Sepsis11.01.11.003--
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder19.19.02.002; 22.12.03.027; 17.02.08.003--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.01.045--
Stomatitis07.05.06.005--
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.004--
Superinfection11.01.08.009--Not Available
Supraventricular tachycardia02.03.03.012--
Syncope24.06.02.012; 17.02.04.008; 02.11.04.015--
Tachycardia02.03.02.007--Not Available
Tendon disorder12.01.07.019; 15.07.01.002--Not Available
Tendon rupture15.07.01.008; 12.01.07.003--Not Available
Tendonitis12.01.07.007; 15.07.01.003--Not Available
Tension19.06.02.005--Not Available
Tension headache19.24.01.009; 17.14.01.004--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytosis01.08.02.001--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue discolouration07.14.02.006--Not Available
The 11th Page    First    Pre   11 12 13 14    Next   Last    Total 14 Pages